Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Investigation of the Effects of Sub-Perceptual Repeat Dosing of Psilocybin on the Behavioural and Cognitive Symptoms of Fragile X Syndrome in Adult Patients

NCT05832255 is registered in ClinicalTrials.gov with Nova Mentis Life Science Corp as lead sponsor.

NCT NCT05832255
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05832255 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Investigation of the Effects of Sub-Perceptual Repeat Dosing of Psilocybin on the Behavioural and Cognitive Symptoms of Fragile X Syndrome in Adult Patients
Lead sponsor
Nova Mentis Life Science Corp
Phase
Phase 2
Overall status
Suspended
Start date
March 28, 2023
Completion date
May 31, 2024
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

behavior, cognitive dysfunction, fragile x syndrome